11Jun 2025
Belinostat enhances ovarian cancer therapy via apoptotic reprogramming

Belinostat enhances ovarian cancer therapy via apoptotic reprogramming

The study shows that the HDAC inhibitor belinostat boosts Bim, Puma, and Noxa expression, suppresses Bcl-xL, and induces apoptosis in SKOV3 and IGROV1-R10 ovarian cancer cells. Belinostat’s efficacy was amplified by co-targeting Bcl-xL or Mcl-1, including in patient-derived organoids. These findings highlight a promising combination strategy leveraging belinostat to overcome resistance and improve ovarian cancer treatment.

  • #oncology

Like

Save

Share